Grigory A. Yanus

Saint Petersburg, SPE 194100, Russian Federation

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

Germline Variants in the Immune Response-Related Genes: Possible Modifying Effect on Age-Dependent BRCA1 Penetrance in Breast Cancer Patient.

Germline Variants in the Immune Response-Related Genes: Possible Modifying Effect on Age-Dependent BRCA1 Penetrance in Breast Cancer Patient.

Journal: Cancers
Published: October 03, 2025

Clinical and Morphological Features of ER-Positive HER2-Negative Breast Tumors with PIK3CA Mutations in Russian Patients.

Clinical and Morphological Features of ER-Positive HER2-Negative Breast Tumors with PIK3CA Mutations in Russian Patients.

Journal: Cancers
Published: May 06, 2025

Hereditary Renal Cancer Syndromes.

Hereditary Renal Cancer Syndromes.

Journal: Medical sciences (Basel, Switzerland)
Published: November 25, 2023

Northern origin of the BRCA2 c.5286 T > G founder allele.

Northern origin of the BRCA2 c.5286 T > G founder allele.

Journal: Breast cancer research and treatment
Published: November 08, 2023

KRAS, NRAS, BRAF, HER2 and MSI Status in a Large Consecutive Series of Colorectal Carcinomas.

KRAS, NRAS, BRAF, HER2 and MSI Status in a Large Consecutive Series of Colorectal Carcinomas.

Journal: International journal of molecular sciences
Published: January 28, 2023

Preparation of Duplex Sequencing Libraries for Archival Paraffin-Embedded Tissue Samples Using Single-Strand-Specific Nuclease P1.

Preparation of Duplex Sequencing Libraries for Archival Paraffin-Embedded Tissue Samples Using Single-Strand-Specific Nuclease P1.

Journal: International journal of molecular sciences
Published: March 26, 2022

Lack of Response to Imatinib in Melanoma Carrying Rare KIT Mutation p.T632I.

Lack of Response to Imatinib in Melanoma Carrying Rare KIT Mutation p.T632I.

Journal: Case reports in oncology
Published: November 01, 2018

High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation.

High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation.

Journal: Cancer letters
Published: July 08, 2015

Development of breast tumors in CHEK2, NBN/NBS1 and BLM mutation carriers does not commonly involve somatic inactivation of the wild-type allele.

Development of breast tumors in CHEK2, NBN/NBS1 and BLM mutation carriers does not commonly involve somatic inactivation of the wild-type allele.

Journal: Medical oncology (Northwood, London, England)
Published: October 31, 2013
Showing 1-9 of 9

Last Updated: 09/26/2026